Sabichi Anita L, Lee J Jack, Taylor Robert J, Thompson Ian M, Miles Brian J, Tangen Catherine M, Minasian Lori M, Pisters Louis L, Caton John R, Basler Joseph W, Lerner Seth P, Menter David G, Marshall James R, Crawford E David, Lippman Scott M
University of Texas M.D. Anderson Cancer Center, Baylor College of Medicine, Houston, Texas, USA.
Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2178-84. doi: 10.1158/1078-0432.CCR-05-0937.
Epidemiologic and clinical data suggest that selenium could prevent prostate cancer, but it has not been shown that supplemental selenium leads to an increased concentration of selenium in prostate tissue compared with adjacent tissue.
We conducted a randomized, controlled, short-term trial of l-selenomethionine (SeMet) versus observation in men with organ-confined prostate cancer. The primary endpoint was the measurement of selenium concentration in prostate tissue and seminal vesicle (SV). We assessed baseline selenium levels in serum and in toenail specimens (reflecting long-term intake) and post-intervention selenium levels in serum, and in prostate and SV tissues using hydride generation atomic fluorescence spectroscopy.
Sixty-six eligible patients were randomly assigned to the SeMet (n = 34) or observation (n = 32) arm; both arms had similar baseline patient characteristics. Baseline serum selenium was similar in the two groups (P = 0.64). Baseline toenail selenium levels were slightly higher in the SeMet group than in the control group (P = 0.07). After the intervention, the mean serum selenium level increased 15% in the SeMet arm and was higher than in the observation arm (P = 0.001). The selenium concentration in prostate tissue was 22% higher in the SeMet arm (n = 26) than in the observation arm (n = 25; 1.80 versus 1.47 ppm; P = 0.003, Wilcoxon rank sum test) and remained significantly higher after adjusting for chronic selenium intake (P = 0.021, ANCOVA). SV selenium concentration was similar in both groups (P = 0.384) and was lower than in prostate tissue.
The present study is the first to show that selenium taken as oral supplementation accumulates preferentially in the human prostate gland as opposed to the SV. These findings support the hypothesis that oral selenium supplementation may contribute to the cancer preventive effects of selenium.
流行病学和临床数据表明,硒可能预防前列腺癌,但与相邻组织相比,补充硒是否会导致前列腺组织中硒浓度升高尚无定论。
我们对器官局限性前列腺癌男性患者进行了一项左旋硒代蛋氨酸(SeMet)与观察对照的随机短期试验。主要终点是测量前列腺组织和精囊(SV)中的硒浓度。我们使用氢化物发生原子荧光光谱法评估了血清和趾甲标本(反映长期摄入量)中的基线硒水平,以及干预后血清、前列腺和SV组织中的硒水平。
66名符合条件的患者被随机分配到SeMet组(n = 34)或观察组(n = 32);两组患者的基线特征相似。两组的基线血清硒水平相似(P = 0.64)。SeMet组的基线趾甲硒水平略高于对照组(P = 0.07)。干预后,SeMet组的平均血清硒水平升高了15%,高于观察组(P = 0.001)。SeMet组(n = 26)的前列腺组织中硒浓度比观察组(n = 25;1.80对1.47 ppm;P = 0.003,Wilcoxon秩和检验)高22%,在调整慢性硒摄入量后仍显著更高(P = 0.021,协方差分析)。两组的SV硒浓度相似(P = 0.384),且低于前列腺组织。
本研究首次表明,口服补充的硒优先在人类前列腺中积累,而非在精囊中。这些发现支持了口服补充硒可能有助于发挥硒的癌症预防作用这一假说。